Core Viewpoint - The stock of Dabo Medical (002901) has shown a recent increase in price and positive financial performance, indicating potential investment opportunities in the medical device sector. Group 1: Stock Performance - As of February 5, 2026, Dabo Medical closed at 50.14 yuan, up 1.62% with a turnover rate of 0.61% and a trading volume of 17,600 shares, resulting in a transaction value of 88.34 million yuan [1] - On February 5, 2026, the net inflow of main funds was 418,700 yuan, accounting for 0.47% of the total transaction value, while retail investors saw a net inflow of 1.17 million yuan, representing 1.33% of the total [1] Group 2: Financing and Margin Trading - On February 5, 2026, the financing buy amounted to 7.38 million yuan, while financing repayment was 9.08 million yuan, resulting in a net repayment of 1.70 million yuan [1] - The total financing balance on February 5, 2026, was 155 million yuan, with a margin trading balance of 155 million yuan [2] Group 3: Financial Metrics and Industry Comparison - Dabo Medical's total market capitalization is 20.76 billion yuan, with a net profit of 425 million yuan, which is significantly higher than the industry average of 208 million yuan [4] - The company reported a gross margin of 71.23% and a net profit margin of 23.92%, both of which are above the industry averages of 50.55% and 9.59%, respectively [4] - For the first three quarters of 2025, Dabo Medical's main revenue was 1.88 billion yuan, a year-on-year increase of 22.69%, and the net profit attributable to shareholders was 425 million yuan, up 77.03% year-on-year [4]

Core Viewpoint - Dabo Medical (002901) shows a positive trend in stock performance and financial metrics, indicating potential growth opportunities in the medical device industry. Financial Performance - As of February 3, 2026, Dabo Medical's stock closed at 49.75 yuan, up 1.12%, with a trading volume of 18,500 lots and a transaction value of 91.64 million yuan [1] - For the first three quarters of 2025, the company reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69%, and a net profit of 425 million yuan, up 77.03% year-on-year [2] - The company's gross profit margin stands at 71.23%, significantly higher than the industry average of 50.55% [2] Market Position - Dabo Medical has a total market capitalization of 20.597 billion yuan, ranking 12th in the medical device industry [2] - The company has a price-to-earnings ratio (P/E) of 36.38, which is lower than the industry average of 97.37, indicating a potentially undervalued stock [2] - The return on equity (ROE) is 12.83%, placing the company 8th in the industry, which reflects strong profitability compared to peers [2] Recent Trading Activity - On February 3, 2026, the net outflow of main funds was 2.7838 million yuan, while retail investors saw a net inflow of 1.1964 million yuan [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable retail interest despite some institutional selling [1]

Core Viewpoint - The stock of Dabo Medical (002901) has shown fluctuations in its trading performance, with a recent closing price of 51.22 yuan, reflecting a decline of 1.31% on January 28, 2026, amidst varying capital flows from different investor categories [1]. Group 1: Stock Performance and Capital Flow - On January 28, 2026, Dabo Medical's stock closed at 51.22 yuan, down 1.31%, with a turnover rate of 1.36% and a trading volume of 39,200 hands, resulting in a transaction amount of 201 million yuan [1]. - The capital flow data on January 28 indicates a net outflow of 4.23 million yuan from institutional investors, accounting for 2.1% of the total transaction amount, while retail investors experienced a net outflow of 1.45 million yuan, representing 0.72% of the total [1]. - Over the past five days, the stock has seen significant fluctuations, with a peak closing price of 51.90 yuan on January 27, 2026, which was a 7.45% increase, followed by a net inflow of 12.99 million yuan from institutional investors on that day [2]. Group 2: Company Financials and Industry Comparison - Dabo Medical's total market capitalization stands at 21.206 billion yuan, significantly higher than the industry average of 11.206 billion yuan, ranking 12th out of 127 companies in the medical device sector [3]. - The company reported a net profit of 425 million yuan, which is substantially higher than the industry average of 208 million yuan, placing it 17th in the industry ranking [3]. - Dabo Medical's gross margin is 71.23%, well above the industry average of 50.94%, indicating strong profitability relative to its peers [3]. - For the first three quarters of 2025, the company achieved a main business revenue of 1.876 billion yuan, reflecting a year-on-year increase of 22.69%, and a net profit growth of 77.03% to 425 million yuan [3].

证券之星消息，截至2026年1月27日收盘，大博医疗(002901)报收于51.9元，上涨7.45%，换手率 2.51%，成交量7.24万手，成交额3.71亿元。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。大博医疗（002901）主营业务：医用高值耗材的生产、研发与销售。 1月27日的资金流向数据方面，主力资金净流入1299.83万元，占总成交额3.51%，游资资金净流出 987.92万元，占总成交额2.67%，散户资金净流出311.91万元，占总成交额0.84%。 该股最近90天内共有1家机构给出评级，买入评级1家。 近5日资金流 ...

Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a substantial growth of 77.03% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up by 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a year-on-year increase of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up by 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 23, 2026, Dabo Medical's stock closed at 50.15 yuan, with an increase of 1.48% [1]. - The trading volume was 20,400 hands, with a total transaction amount of 102 million yuan [1]. - The net outflow of main funds was 1.6977 million yuan, accounting for 1.67% of the total transaction amount, while retail investors saw a net inflow of 6.51 million yuan, representing 6.4% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, one institution has given a buy rating for Dabo Medical [3].

Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][3]. Group 1: Stock Performance - As of January 22, 2026, Dabo Medical's stock closed at 49.42 yuan, down 1.06% with a turnover rate of 0.58% and a trading volume of 16,800 lots, amounting to a transaction value of 83.36 million yuan [1]. - The net outflow of main funds on January 22 was 1.92 million yuan, accounting for 2.31% of the total transaction value, while retail investors saw a net inflow of 1.26 million yuan, representing 1.51% of the total [1]. Group 2: Financial Metrics and Industry Comparison - Dabo Medical's total market capitalization is 20.461 billion yuan, significantly higher than the industry average of 11.31 billion yuan, ranking 12th out of 127 companies in the medical device sector [2]. - The company reported a net profit of 425 million yuan for the first three quarters of 2025, a year-on-year increase of 77.03%, with a gross margin of 71.23%, which is well above the industry average of 50.94% [2]. - The company's return on equity (ROE) stands at 12.83%, placing it 7th in the industry, while its price-to-earnings ratio (P/E) is 36.14, significantly lower than the industry average of 97.34 [2].

Core Viewpoint - Dabo Medical (002901) reported a decline in stock price and mixed capital flow data, indicating potential investor caution despite strong financial performance in recent quarters [1][2]. Financial Performance - For the first three quarters of 2025, Dabo Medical achieved a main operating revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a significant year-on-year growth of 77.03% [2]. - The non-recurring net profit was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company reported a main operating revenue of 666 million yuan, a 17.82% increase compared to the same quarter last year [2]. - The net profit for Q3 2025 was 180 million yuan, showing a year-on-year increase of 77.49% [2]. - The non-recurring net profit for Q3 2025 was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with an investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Capital Flow - On January 7, 2026, Dabo Medical's stock closed at 49.48 yuan, down 1.61%, with a turnover rate of 0.68% and a trading volume of 19,500 hands, resulting in a transaction amount of 97.09 million yuan [1]. - The capital flow data for January 7 indicates a net outflow of 10.69 million yuan from main funds, accounting for 11.02% of the total transaction amount [1]. - Retail investors contributed a net inflow of 8.29 million yuan, representing 8.54% of the total transaction amount [1].

Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a 77.03% increase year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a 17.82% increase year-on-year [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 5, 2026, Dabo Medical's stock closed at 49.63 yuan, up 4.77%, with a turnover rate of 1.07% and a trading volume of 30,900 hands, amounting to a transaction value of 152 million yuan [1]. - On January 5, the net outflow of main funds was 15.42 million yuan, accounting for 10.17% of the total transaction value, while retail investors saw a net inflow of 26.27 million yuan, representing 17.32% of the total transaction value [1].

Core Viewpoint - The company operates in the medical device distribution industry, focusing on high-value medical consumables and IVD diagnostic products, with a strategy to enhance its market share through differentiated operational capabilities and digital applications [2] Group 1: Industry Overview - The medical device distribution industry is characterized by a relatively fragmented market share for the company's core products, which include vascular intervention and surgical products, as well as IVD diagnostic products [2] - The company aims to leverage national sales networks, specialized operational capabilities, and digital development applications to differentiate itself from traditional medical device distributors and pharmaceutical wholesalers [2] Group 2: Business Strategy - The company plans to capitalize on existing mature market shares in the medical device distribution sector, particularly in the context of centralized procurement policies [2] - The company will actively pursue the commercialization of innovative medical devices, supported by encouraging policies for innovation [2] - Focus on centralized management supply for key hospitals during the full implementation phase of the medical reform DRG policy represents a new market segment for the company [2] Group 3: Competitive Positioning - The company's operational capabilities and digital applications are expected to enhance its position in both existing and emerging markets within the medical device distribution field [2] - The company aims for steady growth to improve its industry standing by learning from competitors and maintaining a robust competitive edge [2]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Dabo Medical (002901) as of December 29, 2025, showing a slight decline in stock price and notable changes in capital flow [1][2]. Group 2 - Dabo Medical reported a main revenue of 1.876 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders for the same period was 425 million yuan, up 77.03% year-on-year, while the net profit after deducting non-recurring items was 346 million yuan, an increase of 63.99% [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 666 million yuan, reflecting a year-on-year growth of 17.82% [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, up 77.49% year-on-year, and the net profit after deducting non-recurring items was 123 million yuan, increasing by 38.44% [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan, while the gross profit margin is 71.23% [2]. - Dabo Medical specializes in the production, research, and sales of high-value medical consumables [2]. Group 3 - Over the last 90 days, one institution has given a buy rating for Dabo Medical [3]. - The capital flow data indicates a net outflow of 9.4984 million yuan from main funds, accounting for 12.08% of the total transaction amount, while retail investors saw a net inflow of 8.1568 million yuan, representing 10.37% of the total transaction amount [1].